Skip to main content

Lilly inks deal with Care Capital, NovaQuest Capital to establish BioCritica


INDIANAPOLIS — Drug maker Eli Lilly is partnering with two private investor groups to form a new biotech company based in central Indiana, the company said Monday.

Lilly signed a deal with Care Capital and NovaQuest Capital to establish BioCritica, a privately held biotechnology company that will focus on continued U.S. development and commercialization of the severe sepsis treatment Xigris (drotrecogin alfa [activated]). The new company also will expand its portfolio of critical care medicines for hospitals.

Under a licensing agreement, BioCritica will acquire U.S. development and commercialization rights to Xigris and receive rights to potentially acquire several critical care compounds in preclinical development at Lilly.

This ad will auto-close in 10 seconds